Table 5.
Multivariable Cox Proportional Hazards Model for All Patients
| Parameter | Relapse-Free Survival |
Overall Survival |
||||
|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | P | Hazard Ratio | 95% CI | P | |
| Beta-blocker use, yesv no | 0.52 | 0.31 to 0.88 | .015 | 0.64 | 0.38 to 1.07 | .09 |
| Age, ≥ 50v < 50 years | 0.81 | 0.66 to 1.00 | .05 | 1.04 | 0.83 to 1.3 | .75 |
| Race, blackv non-black | 1.37 | 1.06 to 1.77 | .018 | 1.47 | 1.13 to 1.93 | .005 |
| Stage, IIIv I/II | 1.70 | 1.38 to 2.08 | < .001 | 1.77 | 1.42 to 2.21 | < .001 |
| Grade, IIIv I/II | 1.18 | 0.92 to 1.53 | .19 | 1.35 | 1.02 to 1.78 | .039 |
| Hormone receptor status, positivev negative | 0.74 | 0.48 to 1.13 | .16 | 0.76 | 0.47 to 1.23 | .26 |
| HER2 status, positivev negative | 1.31 | 0.92 to 1.87 | .14 | 1.03 | 0.69 to 1.53 | .90 |
| Triple-negative tumor, nov yes | 0.71 | 0.44 to 1.14 | .16 | 0.61 | 0.36 to 1.03 | .07 |
| LVI, positivev negative | 1.89 | 1.54 to 2.32 | < .001 | 1.75 | 1.4 to 2.18 | < .001 |
| BMI, kg/m2 | ||||||
| 25-29v < 25 | 0.99 | 0.77 to 1.27 | .92 | 1.03 | 0.78 to 1.36 | .83 |
| 30+v < 25 | 1.16 | 0.9 to 1.50 | .26 | 1.25 | 0.95 to 1.64 | .11 |
| Diabetes, yesv no | 1.20 | 0.77 to 1.88 | .41 | 1.63 | 1.07 to 2.48 | .022 |
| Hypertension, yesv no | 1.08 | 0.8 to 1.45 | .60 | 1.00 | 0.73 to 1.37 | .98 |
| ACEI/ARB use, yesv no | 0.82 | 0.54 to 1.26 | .37 | 0.99 | 0.65 to 1.51 | .96 |
Abbreviations: LVI, lymphovascular invasion; BMI, body mass index; HER2, human epidermal growth factor receptor 2; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.